These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23156819)

  • 1. Doctors of interest. Recipients of suspect drug-company payments academic medical centers, have drawing attention of federal fraud enforcers.
    Carlson J
    Mod Healthc; 2012 Aug; 42(34):6-7, 16, 1. PubMed ID: 23156819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HHS' fourth fraud alert puts spotlight on drug companies.
    Burda D; Scott L
    Mod Healthc; 1994 Aug; 24(35):26, 34. PubMed ID: 10136147
    [No Abstract]   [Full Text] [Related]  

  • 3. Left in the lurch. With Corrigan's recusal from hospital cases, HHS' inspector general's office has a gap at the top after months of indecision.
    Taylor M
    Mod Healthc; 2004 Jun; 34(23):6-7, 1. PubMed ID: 15216609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new civil defense. Using powers dormant since '97, HHS' inspector general begins wielding civil monetary penalties as weapon in fight against fraud.
    Taylor M
    Mod Healthc; 2002 Jul; 32(30):40-2. PubMed ID: 12195668
    [No Abstract]   [Full Text] [Related]  

  • 5. Mirror, mirror on the wall--evaluating Fair Market Value for manufacturer-physician consulting arrangements.
    Eaton F; Reid J
    Food Drug Law J; 2010; 65(1):141-57, iii. PubMed ID: 24475537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When he speaks, healthcare listens. HHS' inspector general's longtime chief counsel elicits praise--along with some criticism.
    Taylor M
    Mod Healthc; 1999 Oct; 29(40):42. PubMed ID: 10621453
    [No Abstract]   [Full Text] [Related]  

  • 7. Watchdog gets touch on Medicare fraud. Inspector general has strong-armed nearly $10 million in hospital settlements.
    Burda D
    Mod Healthc; 1991 Apr; 21(14):32-8. PubMed ID: 10109868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting fraud.
    Blesch G
    Mod Healthc; 2010 Jun; 40(25):6-7, 1. PubMed ID: 20632691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Financial conflicts of interest in physicians' relationships with the pharmaceutical industry--self-regulation in the shadow of federal prosecution.
    Studdert DM; Mello MM; Brennan TA
    N Engl J Med; 2004 Oct; 351(18):1891-900. PubMed ID: 15509824
    [No Abstract]   [Full Text] [Related]  

  • 10. HHS: don't call on self-referrals. Inspector general's office narrows scope of disclosure.
    Blesch G
    Mod Healthc; 2009 Mar; 39(13):17. PubMed ID: 19405429
    [No Abstract]   [Full Text] [Related]  

  • 11. Medicare and state health care programs and program fraud civil remedies: fraud and abuse; civil money penalties inflation adjustments--Office of Inspector General, HHS. Final rule.
    Fed Regist; 1996 Oct; 61(195):52299-301. PubMed ID: 10162168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doctors and drug companies--scrutinizing influential relationships.
    Campbell EG
    N Engl J Med; 2007 Nov; 357(18):1796-7. PubMed ID: 17978288
    [No Abstract]   [Full Text] [Related]  

  • 13. Conflict crimps IT policy. HHS' rules called hindrance to technology.
    Morrissey J
    Mod Healthc; 2004 Aug; 34(34):9. PubMed ID: 15449873
    [No Abstract]   [Full Text] [Related]  

  • 14. Physician financial relationships in the new regulatory environment.
    Roberts RD
    Physician Exec; 1994 Nov; 20(11):50-2. PubMed ID: 10140898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HHS' inspector general warns providers about joint ventures. With sham deals increasing, office cautions that suspicious cases may trigger antikickback statute.
    Taylor M
    Mod Healthc; 2003 Apr; 33(17):8-9. PubMed ID: 12747121
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug marketing from an Office of Inspector General enforcement perspective.
    Foley LA
    Food Drug Law J; 1995; 50(2):309-12. PubMed ID: 10342999
    [No Abstract]   [Full Text] [Related]  

  • 17. Why do drug companies fear this man?
    Simons J
    Fortune; 2003 Oct; 148(9):167-8, 170, 172. PubMed ID: 14584310
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug companies will have to report all payments to US doctors from March 2014.
    Roehr B
    BMJ; 2013 Feb; 346():f826. PubMed ID: 23393117
    [No Abstract]   [Full Text] [Related]  

  • 19. Grassley asks GAO to launch review of Rehnquist's office. Agency will scrutinize HHS inspector general's personnel changes and impact on quality of work.
    Taylor M
    Mod Healthc; 2002 Oct; 32(43):8-9. PubMed ID: 12436768
    [No Abstract]   [Full Text] [Related]  

  • 20. The Inspector General's fraud alerts: questionable utility for hospitals and practitioners.
    Peregrine MW; Thiel DK
    Med Staff Couns; 1993; 7(1):79-87. PubMed ID: 10123463
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.